Drug Patents owned by Antares Pharma Inc

1. List of Tlando drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11304960 ANTARES PHARMA INC Steroidal compositions
Jan, 2029

(5 years from now)

US8778922 ANTARES PHARMA INC Steroidal compositions
Jan, 2029

(5 years from now)

US8865695 ANTARES PHARMA INC Steroidal compositions
Jan, 2029

(5 years from now)

US11364249 ANTARES PHARMA INC High-strength testosterone undecanoate compositions
Nov, 2030

(7 years from now)

US9943527 ANTARES PHARMA INC High-strength testosterone undecanoate compositions
Nov, 2030

(7 years from now)

US10226473 ANTARES PHARMA INC High-strength testosterone undecanoate compositions
Nov, 2030

(7 years from now)

US11311555 ANTARES PHARMA INC High-strength testosterone undecanoate compositions
Nov, 2030

(7 years from now)

US9949985 ANTARES PHARMA INC High-strength testosterone undecanoate compositions
Nov, 2030

(7 years from now)

US10716794 ANTARES PHARMA INC High-strength testosterone undecanoate compositions
Nov, 2030

(7 years from now)

US11433083 ANTARES PHARMA INC High-strength testosterone undecanoate compositions
Nov, 2030

(7 years from now)

US11464735 ANTARES PHARMA INC Fixed dose oral testosterone undecanoate compositions and use thereof
Apr, 2041

(18 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Mar 28, 2025

Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient

Market Authorisation Date: 28 March, 2022

Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; Primary hypogonadism (congenital or acquired); Hypogonadotropic hypogonadism (congenital or acquired).

Dosage: CAPSULE;ORAL

More Information on Dosage

2. List of Xyosted (autoinjector) drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10478560 ANTARES PHARMA INC Prefilled syringe injector
Jan, 2026

(2 years from now)

US9629959 ANTARES PHARMA INC Prefilled syringe jet injector
Jan, 2026

(2 years from now)

US8562564 ANTARES PHARMA INC Prefilled syringe jet injector
Jan, 2026

(2 years from now)

US11446441 ANTARES PHARMA INC Prefilled syringe injector
Jan, 2026

(2 years from now)

US9180259 ANTARES PHARMA INC Prefilled syringe jet injector
Jan, 2026

(2 years from now)

US9533102 ANTARES PHARMA INC Prefilled syringe jet injector
Jan, 2026

(2 years from now)

US8021335 ANTARES PHARMA INC Prefilled syringe jet injector
Oct, 2026

(3 years from now)

US11497753 ANTARES PHARMA INC Hazardous agent injection system
Mar, 2030

(7 years from now)

US10279131 ANTARES PHARMA INC Injection device with cammed RAM assembly
Jul, 2031

(8 years from now)

US10905827 ANTARES PHARMA INC Injection device with cammed ram assembly
Aug, 2031

(8 years from now)

US10357609 ANTARES PHARMA INC Needle assisted jet injection device having reduced trigger force
Aug, 2031

(8 years from now)

US11446440 ANTARES PHARMA INC Needle assisted injection device having reduced trigger force
Aug, 2031

(8 years from now)

US10821072 ANTARES PHARMA INC Needle assisted jet injection administration of testosterone compositions
Jun, 2033

(10 years from now)

US10881798 ANTARES PHARMA INC Needle assisted injection device having reduced trigger force
Feb, 2034

(11 years from now)

US11160751 ANTARES PHARMA INC Hematocrit modulation through needle assisted jet injection of testosterone
Oct, 2034

(11 years from now)

US10912782 ANTARES PHARMA INC Needle assisted injection administration of testosterone compositions
Feb, 2035

(12 years from now)

US10238662 ANTARES PHARMA INC Needle assisted jet injection administration of testosterone compositions
Feb, 2035

(12 years from now)

US11191908 ANTARES PHARMA INC Syringe shock absorber for use in an injection device
Oct, 2035

(12 years from now)

US9744302 ANTARES PHARMA INC Needle assisted jet injection device having reduced trigger force
Nov, 2035

(12 years from now)

US9950125 ANTARES PHARMA INC Needle assisted jet injection administration of testosterone compositions
Sep, 2036

(13 years from now)

US10646495 ANTARES PHARMA INC Testosterone ester triglyceride formulations
Aug, 2038

(15 years from now)

Drugs and Companies using TESTOSTERONE ENANTHATE ingredient

Market Authorisation Date: 28 September, 2018

Treatment: Method of administering testosterone enanthate subcutaneously

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in